LYGADDO

Pharmaceuticals, namely, pharmaceutical preparations for the treatment of viral infections; pharmaceutical preparations for the treatment of cardiovascular disorders and conditions; pharmaceutical preparations for the treatment of respiratory disorders and conditions; pharmaceutical preparations for the treatment of fungal diseases and disorders; pharmaceutical preparations for the treatment of liver disease; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of HIV/AIDS and hepatitis; pharmaceutical preparations for the treatment of inflammatory diseases and disorders